Table IV.
Treatment and dose modifications all cycles for all pts (N = 62)
| Dose Changes | # pts | Median # cycles (range) | Reason for dose modification | ||||
|---|---|---|---|---|---|---|---|
| ANC | PN | F&N | Hearing | Unknown | |||
| Full Dose | 55 (89%) | ||||||
| GCSF 20 mcg/kg/d | |||||||
| cycle 1-6 | 10 (16%) | 2 (2-6) | 10 | 0 | 0 | 0 | 0 |
| cycles > 6 | 3 (5%) | 8 | 3 | 0 | 0 | 0 | 0 |
| T 200 mg/m2 | |||||||
| cycle 1-6 | 4 (6%) | 3 (3-4) | 1 | 2 | 1 | 0 | 0 |
| cycles > 6 | 12 (19%) | 8 (7-10) | 2 | 9 | 4 | 0 | 0 |
| T 175 mg/m2 | |||||||
| cycle 1-6 | 2 (5%) | 5 (4-6) | 0 | 0 | 1 | 0 | 1 |
| cycles > 6 | 6 (15%) | 8 (8-10) | 1 | 5 | 1 | 0 | 1 |
| T 150 mg/m2 | |||||||
| cycle 1-6 | 1 | 6 | 0 | 1 | 0 | 0 | 0 |
| cycles > 6 | 1 | 9 | 0 | 1 | 0 | 0 | 0 |
| C 500 mg/m2 | |||||||
| cycle 1-6 | 1 | 3 | 1 | 0 | 0 | 0 | 0 |
| cycles > 6 | 3 (5%) | 9 (7-9) | 2 | 0 | 0 | 0 | 1 |
| P 50 mg/m2 | |||||||
| cycle 1-6 | 3** | 6 | 0 | 0 | 0 | 1 | 1 |
*
more than one reason for dose modification in some patients.
**
for delayed thrombocytopenia